Expert Interview
Discussing Sumitomo Pharma's FDA approval for GEMTESA (vibegron) for men with overactive bladder symptoms receiving pharmacological therapy for benign prostatic hyperplasia.
Ticker(s): DNPUFInstitution: Specialty Physicians of Illinois
- Board certified Urologist, Chairman of the Department of Surgery, and Program Director for the Urology residency program,
- Treats entire spectrum of urologic diseases, typically seeing 5000-600 patients per month and performing 60-70 surgeries.
- Manages treatment for 100-120 patients with hypogonadism
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
